Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and is a fast progressive disease when left untreated. Identification of potential biomarkers in NSCLC is an ongoing area of research that aims to detect, diagnose, and prognosticate patients early to optimize treatment. We review the role of interleukin-11 (IL11), a stromal-cell derived pleiotropic cytokine with profibrotic and cellular remodeling properties, as a potential biomarker in NSCLC. This review identifies the need for biomarkers in NSCLC, the potential sources of IL11, and summarizes the available information leveraging upon published literature, publicly available datasets, and online tools. We identify accumulating evidence suggesting IL11 to be a potential biomarker in NSCLC patients. Further in-depth studies into the pathophysiological effects of IL11 on stromal-tumor interaction in NSCLC are warranted and current available literature highlights the potential value of IL11 detection as a diagnostic and prognostic biomarker in NSCLC.

An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma

“…IL‐11 has been shown to be upregulated by cancer cells and cancer‐associated fibroblasts in lung adenocarcinoma, leading to cancer progression 18,39 . In addition, increased IL‐11 mRNA expression in lung cancer patients is associated with worse overall survival 40 . We used combinatorial protein engineering to identify a variant of IL‐11, containing four mutations (D19G, T21I, L57P, and G62R), that improved binding to IL‐11R.…”

“…18,39 In addition, increased IL-11 mRNA expression in lung cancer patients is associated with worse overall survival. 40 We used combinatorial protein engineering to identify a variant of IL-11, containing four mutations (D19G, T21I, L57P, and G62R), that improved binding to IL-11R. While two of these mutations are found outside of the previously defined Site I interface that binds to IL-11R, it is possible the receptor binding site is broader than proposed or these residues could have effects on protein conformation via neighboring interactions.…”

Identification of Immune-Related Genes and Construction of Metastasis Prediction Model for Non-Small Cell Lung Cancer

“…IL11 encodes interleukin (IL)-11, a cytokine belonging to IL-6 family, which has anti-in ammation properties. It can promote tumor invasion and metastasis by activating relevant pathways (12), and is associated with poor prognosis in multiple cancer (13,14). SH2D1B is a member of the SH2 domain protein family that mainly modulates the functions of SLAMF receptor family.…”

A biotin-guided near-infrared fluorescent probe for imaging hydrogen sulfide and differentiating cancer cells

“…Cancer biomarkers are recognized as targets for tumor imaging and can be used clinically for accurate diagnosis of tumors. 3–5 In particular, fluorescence-based methods have been successfully developed for in situ and real-time visualization of cancer biomarkers and further detecting cancers. 6,7 Usually, activatable fluorescent probes are rationally designed to be initially quenched until activation by specific biomarkers.…”